TRT on TikTok: Separating testosterone facts from hype

What did @hormonedoctor actually say?

The creator walked through a fairly specific clinical chain: high-dose weekly testosterone (200mg) tanks SHBG by suppressing hepatic production, low SHBG means more free testosterone, and that free testosterone converts aggressively to estrogen and DHT, causing hair loss, erectile dysfunction, and mood problems. Their fix? Lower the dose, increase injection frequency, investigate thyroid, liver, A1C, and body composition. They also suggested reducing aromatase inhibitors because estrogen at the upper end of normal might actually raise SHBG back up. They were careful to say this wasn't medical advice and framed it as what they'd do with a patient under their care.

That's more clinical nuance than most TRT content on TikTok. Whether it's accurate is a different question.

Does the science back this up?

Mostly, yes. The SHBG suppression mechanism is well-documented, and the cascade logic holds. But some of the framing oversimplifies what's actually happening.

Androgens do suppress hepatic SHBG synthesis. A 2016 review by Simó et al. in Endocrine Reviews confirmed that both testosterone and insulin are among the primary suppressors of SHBG production in hepatocytes. That part is solid. The link between supraphysiologic free testosterone and increased aromatization is also well-established. Aromatase (CYP19A1) activity scales with substrate availability, and adipose tissue is the main conversion site, which is why the creator's question about body weight is clinically relevant.

The claim that estrogen at the upper normal range upregulates SHBG is supported. Estradiol is actually a positive regulator of SHBG production in the liver, which is the opposite of what testosterone does. Hammes et al. (2005, Cell) and earlier work from Hammond's group established this bidirectional hormonal regulation clearly. So the idea of backing off an aromatase inhibitor to let estrogen nudge SHBG upward is not unreasonable, though it requires careful monitoring.

What did they get wrong (or right)?

The mechanism is largely right. The oversimplification is in degree and causality.

Saying SHBG will "tank" on 200mg weekly is plausible but not universal. SHBG suppression varies significantly by individual genetics, baseline liver function, insulin sensitivity, and body composition. A lean, insulin-sensitive person at 200mg weekly may not crash their SHBG the way the creator implies. This is worth stating clearly rather than presenting it as an inevitable outcome.

The DHT claim is also real but incomplete. Yes, free testosterone converts to DHT via 5-alpha reductase, and yes, DHT is associated with androgenic alopecia in genetically susceptible individuals. But framing hair loss as a direct consequence of elevated free T on TRT, without mentioning genetic predisposition, overstates the certainty. Most men on TRT do not experience significant hair loss specifically because of SHBG changes.

Credit where it's due: recommending split dosing over single weekly injections to smooth hormone curves is consistent with pharmacokinetic data. Dobs et al. (2002, Journal of Clinical Endocrinology and Metabolism) showed that injection frequency affects peak-to-trough hormone variability significantly. And asking about thyroid and metabolic markers before chasing SHBG with dose adjustments is exactly the right clinical instinct.

What should you actually know?

SHBG is not just a nuisance protein to minimize. It is a biomarker that reflects your metabolic health, and chasing low SHBG numbers without addressing root causes is backwards medicine.

If your SHBG is low on TRT, the first questions should be: Are you insulin resistant? Do you have fatty liver? Is your thyroid underactive? All of these independently suppress SHBG, and adding more testosterone to the equation will not fix any of them. A 2019 analysis published in Frontiers in Endocrinology by Pugeat et al. reinforced that SHBG is a sensitive marker of insulin resistance and hepatic fat accumulation, independent of exogenous hormone use.

On aromatase inhibitors: these drugs are powerful and frequently overused in TRT contexts. Crashing estrogen to near-zero causes bone density loss, joint pain, cognitive fog, and cardiovascular risk. The creator's caution about "wanting estrogen" and targeting the upper end of the normal range reflects a more sophisticated approach than the reflexive AI-dose-anastrozole pattern common in online TRT communities. That said, "upper end of normal" means different things across labs, and this decision should never be self-managed.

• SHBG suppression on TRT is real but variable, not guaranteed
• Free testosterone driving aromatization is a legitimate concern, especially in men with higher body fat
• Split dosing reduces hormone variability and is supported by pharmacokinetic data
• Estradiol is a positive regulator of SHBG in the liver, the opposite of testosterone
• Metabolic health fixes (weight loss, thyroid treatment, blood sugar control) can raise SHBG without changing your TRT dose